David A. Lamond joined Quince Therapeutics’ Board of Directors in December 2015 and serves as its Chairperson. Since April 2016, Mr. Lamond has served as president of En Pointe LLC, an investment firm. From 2011 to 2016, he served as the President, Chief Executive Officer and Chief Investment Officer of Lamond Capital Partners LLC. Mr. Lamond also is currently a member of the board of directors of Applied Molecular Transport (AMTI), a biopharmaceutical company, and Lucira Health Inc, a molecular diagnostics company. He previously served on the board of Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. In addition, Mr. Lamond is on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.